Financials Fortress Biotech, Inc.

Stocks

FBIO

US34960Q3074

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-27 EDT			5-day change	1st Jan Change
1.930 ^USD	+3.21%		-0.52%	-47.27%

10-01	Fortress Biotech, Inc. Repays Remaining $15 Million Outstanding Principal Under Oaktree Agreement	CI
08-13	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Projected Income Statement: Fortress Biotech, Inc.

Projected Income Statement - Annual - Fortress Biotech, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	68.79	75.74	84.51	57.68	63.26	78.79	113.2
Change	-	10.11%	11.58%	-31.76%	9.69%	24.55%	43.73%
EBITDA	-188.5	-	-	-107.3	-65.56	-	-
Change	-	-	-	-	38.89%	-	-
EBIT ¹	-188.5	-203.6	-142.3	-110.4	-70.22	-32.9	-16.11
Change	-	-7.97%	30.08%	22.46%	36.38%	53.16%	51.02%
Interest Paid ¹	-15.31	-13.64	-15.32	-13.53	-10.11	-9.844	-10
Earnings before Tax (EBT) ¹	-164.4	-213.5	-153.6	-120.5	-33.54	125.3	-23.11
Change	-	-29.88%	28.03%	21.54%	72.18%	473.54%	-118.45%
Net income ¹	-64.7	-86.58	-68.67	-46	-1.882	88.25	-37.81
Change	-	-33.8%	20.68%	33.02%	95.91%	4,789%	-142.85%
Announcement Date	3/28/22	3/30/23	3/28/24	3/31/25	3/31/26	-	-

¹USD in Million

Estimates

Projected Income Statement - Quarterly - Fortress Biotech, Inc.

Fiscal Period: December	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	21.08	18.28	23.92	18.89	16.53	16.4	12.43	17.39	34.75	20.59	13.03	14.9	14.63	15.12	13.14	16.41	17.63	16.08	16.04	18.72	21.58	22.46
Change	-	-13.32%	30.91%	-21.06%	-12.49%	-0.75%	-24.23%	39.88%	99.88%	-40.75%	-36.71%	14.32%	-1.79%	3.36%	-13.1%	24.92%	7.42%	-8.8%	-0.25%	16.71%	15.26%	4.12%
EBITDA	-40.38	-62	-47.27	-50.93	-50.73	-	-	-	-	-	-35.38	-26.6	-	-23.39	-	-	-	-3.632	-	-	-	-
Change	-	-53.53%	23.76%	-7.73%	0.38%	-	-	-	-	-	-	24.81%	-	-	-	-	-	-	-	-	-	-
EBIT ¹	-40.38	-62	-47.27	-50.93	-50.73	-54.63	-58.87	-50.1	-13.76	-142.4	-36.57	-27.79	-22.1	-23.84	-22.32	-36.47	-6.811	-4.789	-7.739	-10.01	-7.689	-7.462
Change	-	-53.53%	23.76%	-7.73%	0.38%	-7.69%	-7.75%	14.88%	72.54%	-934.84%	74.32%	24.01%	20.49%	-7.88%	6.37%	-63.43%	81.33%	29.69%	-61.6%	-29.29%	23.16%	2.95%
Charge d'intérêts ¹	-4.444	-5.915	-2.35	-3.154	-3.393	-4.745	-4.296	-6.425	-2.534	-2.06	-2.602	-2.122	-6.209	-2.594	-2.805	-2.518	-2.742	-2.041	-3.368	-1.476	-2.5	-2.5
Earnings before Tax (EBT) ¹	-45.86	-68.04	-49.48	-53.93	-53.06	-57	-55.14	-59.3	-10.58	-152	-39.02	-28.82	-26.62	-81.29	-24.69	-11.65	8.853	-6.213	142.3	0.922	-8.989	-8.962
Change	-	-48.35%	27.28%	-9%	1.61%	-7.42%	3.25%	-7.54%	82.15%	-1,336.44%	74.33%	26.14%	7.63%	-205.3%	69.62%	52.8%	175.97%	-170.18%	2,390.26%	-99.35%	-1,074.95%	0.3%
Net income ¹	-20.78	-31.56	-15.76	-21.36	-22.51	-26.95	-21.54	-24.78	-5.045	-66.96	-17.73	-13.34	-15.04	-6.765	-12.72	13.36	3.675	-6.198	108.4	-2.476	-8.831	-8.811
Change	-	-51.89%	50.07%	-35.51%	-5.41%	-19.71%	20.08%	-15.04%	79.64%	-1,227.23%	73.52%	24.77%	-12.75%	55.02%	-87.95%	205.03%	-72.48%	-268.65%	1,848.39%	-102.28%	-256.66%	0.23%
Announcement Date	11/15/21	3/28/22	5/12/22	8/11/22	11/14/22	3/30/23	5/15/23	8/14/23	11/14/23	3/28/24	5/15/24	8/13/24	11/14/24	3/31/25	5/15/25	8/14/25	11/14/25	3/31/26	5/14/26	8/13/26	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Fortress Biotech, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027
Net Debt	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-
Announcement Date	3/28/22	3/30/23	3/28/24	3/31/25	3/31/26	-	-

Estimates

Cash Flow Forecast: Fortress Biotech, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025
CAPEX ¹	1.926	4.566	2.715	0.063	-	-
Change	-	137.07%	-40.54%	-97.68%	-	-
Free Cash Flow (FCF) ¹	-55.83	-63.05	-116.4	-100.1	-53.01	-47.29
Change	-	-12.94%	-84.67%	14.01%	47.06%	10.79%
Announcement Date	3/31/21	3/28/22	3/31/23	3/28/24	3/31/25	3/31/26

¹USD in Million

Estimates

Forecast Financial Ratios: Fortress Biotech, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-274.08%	-	-	-186.02%	-103.63%	-	-
EBIT Margin (%)	-	-274.08%	-268.76%	-168.43%	-191.38%	-111%	-41.75%	-14.23%
EBT Margin (%)	-	-238.92%	-281.83%	-181.79%	-209%	-53.01%	158.98%	-20.41%
Net margin (%)	-	-94.06%	-114.3%	-81.25%	-79.75%	-2.97%	112%	-33.39%
FCF margin (%)	-	-	-	-	-	-	-	-
FCF / Net Income (%)	-	-	-	-	-	-	-	-
Profitability
ROA	-21.22%	-29.54%	-36.83%	-37.68%	-41.3%	-26.62%	-	-
ROE	-76.42%	-77.95%	-155.06%	-597.36%	424,052.63%	-108.74%	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-0.06x	-0.19x	-	-	-
Debt / Free cash flow	-	-	-	-0.08x	-0.35x	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	6.64%	3.58%	-	-	-	-	-
CAPEX / EBITDA (%)	-	-2.42%	-	-	-	-	-	-
CAPEX / FCF (%)	-	-	-	-	-	-	-	-
Items per share
Cash flow per share ¹	-	-21.4	-30.28	-	-	-	-	-
Change	-	-	-41.52%	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
EPS ¹	-	-11.85	-14.55	-8.47	-2.69	-0.07	2.55	-1
Change	-	-	-22.78%	41.79%	68.24%	97.4%	3,742.86%	-139.22%
Nbr of stocks (in thousands)	-	6,642	7,241	18,131	27,605	31,038	33,351	33,351
Announcement Date	-	3/28/22	3/30/23	3/28/24	3/31/25	3/31/26	-	-